Floatz logo

msc1936369b

Locally Advanced or Metastatic Solid Tumors

Merck KGaA, Darmstadt, GermanyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Locally Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Atezolizumab
Genentech, Inc.
Phase 2B
Pembrolizumab
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2CCC
gh21
Suzhou Genhouse Bio Co., Ltd.
Phase 2CCC
cvl237 tablets
Convalife (Shanghai) Co., Ltd.
Phase 2CCC
Garsorasib
Suzhou Genhouse Bio Co., Ltd.
Phase 2CCC

View all 46 →

Same molecule, other indications

msc1936369b is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →